Evaluating an Acquisition from the Target Firm's Viewpoint

Evaluating acquisitions is a delicate matter because it is difficult to assume what would have happened in the absence of a deal. This book tries to assess Novartis¿ acquisition in terms of the impact on the Slovenian generic pharmaceutical company Lek. Facing several problems with how to measure the effects of M&A on the acquired firm, success can be assessed from two main aspects: a.) The degree to which previously set goals have been reached; and b.) The performance of the acquired firm in comparison to its peers in key areas of the sector. With insights from 4 C-level members of Lek and Krka, this book offers a unique understanding of reasons for taking very different paths of two leading Slovenian companies in the last 20 years.